The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Unanswered questions that remain in FLT3-mutated AML
Mark Levis, MD, PhD, Johns Hopkins University, Baltimore, MD, discusses unanswered questions that remain in FLT3-mutated acute myeloid leukemia (AML), particularly surrounding the treatment of older patients. Another challenge mentioned is addressing the issue of multiclonality in FLT3-ITD AML. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
